NCT00994643 2025-04-30
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Phase 2 Completed
Clinical Trials
8 trialsNCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01181258 2018-02-06
MT2009-15
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00697671 2013-07-16
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00010192 2013-06-06
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002649 2013-02-28
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00001430 2008-03-04
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed